Physician profile
Nevin Murthy
NPI 1093100240
$2,506.44
in general payments reported to CMS, 2019-2025
27 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.61 · 2021: $409 · 2022: $603 · 2023: $452 · 2024: $657 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448 · Education: $19.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,448.00 |
| Education | $19.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $352.02 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $336.00 | 2021-2024 | Farxiga, Lokelma |
| Alexion Pharmaceuticals, INC. | $204.49 | 2021-2024 | Strensiq, Ultomiris |
| Mallinckrodt Hospital Products INC. | $203.49 | 2022-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $177.58 | 2021-2025 | Jynarque, Voyxact |
| Amgen INC. | $166.04 | 2022-2025 | Tavneos, Aranesp, Parsabiv |
| Novartis Pharmaceuticals Corporation | $135.99 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.71 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $100.99 | 2022-2023 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $96.29 | 2022-2024 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $66.72 | 2022-2023 | Rayaldee |
| Aurinia Pharma U.S., INC. | $61.85 | 2024-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $58.30 | 2022-2023 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $56.05 | 2022-2024 | Veltassa |
| Akebia Therapeutics INC | $50.53 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $48.89 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $42.41 | 2022-2023 | |
| Ardelyx, INC. | $34.48 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.57 | 2025 | Jardiance |
| Alvogen INC | $23.86 | 2024 | Teriparatide |
| Recor Medical INC | $21.94 | 2024 | Paradise Renal Denervation System |
| Amag Pharmaceuticals, INC. | $20.45 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.40 | 2021 | |
| Kyowa Kirin, INC. | $19.65 | 2024 | Crysvita |
| Medtronic, INC. | $17.07 | 2023 | Onyx Frontier |
| Daiichi Sankyo INC. | $16.81 | 2022 | |
| Biomerieux INC | $14.86 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nevin Murthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.